Stonepine Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Stonepine Capital Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-93,968	Closed	-$2.36M	–	70
2025 Q1	$2.36M	Sell	93,968 -106,032	-53%	-$2.68M	2.3%	17
2024 Q4	$5.5M	Sell	200,000 -278,659	-58%	-$7.77M	4.44%	4
2024 Q3	$13.8M	Sell	478,659 -6,341	-1%	-$173K	8.71%	3
2024 Q2	$12M	Buy	485,000 +91,366	+23%	+$2.59M	10.97%	4
2024 Q1	$12.7M	Buy	393,634 +131,764	+50%	+$4.9M	10.05%	4
2023 Q4	$10.6M	Sell	261,870 -540,674	-67%	-$19.9M	4.6%	7
2023 Q3	$27.7M	Buy	802,544 +119,880	+18%	+$4.67M	9.21%	5
2023 Q2	$27.8M	Sell	682,664 -99,625	-13%	-$4.06M	10.01%	4
2023 Q1	$30.2M	Buy	782,289 +587,453	+302%	+$24.1M	10.14%	2
2022 Q4	$8.65M	Buy	+194,836	New	+$8.2M	3.64%	9
2021 Q4	–	Sell	-244,205	Closed	-$12.8M	–	27
2021 Q3	$12.8M	Buy	+244,205	New	+$14.5M	5.85%	4
2021 Q2	–	Sell	-10,000	Closed	-$771K	–	30
2021 Q1	$771K	Buy	+10,000	New	+$921K	0.42%	27

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stonepine Capital Management's LKFT Position: Q2 2025 in Review

Stonepine Capital Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2025, closing a stake of 93,968 shares — an estimated $2.36M sold.

Stonepine Capital Management first reported a position in LKFT in Q1 2021 and held it in 12 quarters. The position peaked at $30.2M in Q1 2023. 85 funds tracked by Wall St. Rank hold LKFT as of Q2 2025.

Stonepine Capital Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2025 after selling out during the quarter.
Stonepine Capital Management sold 93,968 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2025, an estimated $2.36M.
Stonepine Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 12 quarters.
Stonepine Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $30.2M in Q1 2023.
85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2025.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.